Grifols (NASDAQ:GRFS) Stock Rating Lowered by Zacks Research

Grifols (NASDAQ:GRFS) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, August 17th. JPMorgan Chase & Co. lowered their target price on Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Monday, October 26th. Finally, Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. One analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Grifols has an average rating of “Sell” and an average target price of $9.00.

Grifols Stock Up 0.6%

Shares of GRFS opened at $8.61 on Tuesday. The firm has a market cap of $5.86 billion, a P/E ratio of 45.32, a price-to-earnings-growth ratio of 0.33 and a beta of 0.75. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.81 and a current ratio of 2.33. Grifols has a 52 week low of $6.96 and a 52 week high of $9.77. The firm’s 50-day simple moving average is $7.62 and its 200 day simple moving average is $8.00.

Hedge Funds Weigh In On Grifols

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its stake in Grifols by 10.1% in the 1st quarter. Bank of New York Mellon Corp now owns 16,419 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,511 shares in the last quarter. Signaturefd LLC grew its position in shares of Grifols by 68.7% during the 3rd quarter. Signaturefd LLC now owns 4,372 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 1,781 shares in the last quarter. Versant Capital Management Inc grew its position in shares of Grifols by 36.0% during the 2nd quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,842 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Grifols by 41.1% during the third quarter. GAMMA Investing LLC now owns 6,588 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,918 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Grifols by 14.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,259 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 2,844 shares during the period.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.